The once-daily pill also helped 75 per cent of patients who received the highest dose of orforglipron lower their A1C level - ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the ...

Eli Lilly's experimental GLP-1 pill, orforglipron, showed promising results in a late-stage trial, aiding weight loss by 10.5 ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in ...

Health insurance will grow more expensive in many corners of the market in 2026, and some coverage may shrink.

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...

Pricey prescriptions and nagging medical costs are swamping some insurers and employers now. Patients may start paying for it next year.